Biomarkers for Alzheimer's disease: ready for the next step
Author(s) -
Paul B. Rosenberg,
Argye E. Hillis
Publication year - 2009
Publication title -
brain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.142
H-Index - 336
eISSN - 1460-2156
pISSN - 0006-8950
DOI - 10.1093/brain/awp184
Subject(s) - disease , alzheimer's disease , medicine , neuroscience , psychology , pathology
As potential disease-modifying treatments for Alzheimer's disease advance into phase II and III human trials, it is apparent that biomarker development will be needed for several reasons. The most relevant of these include the ability to detect treatment response sensitively, to improve understanding of the effect of drugs that target disease mechanisms, and to identify Alzheimer's disease in its pre-clinical stage. We have reviewed several recent papers published in Brain , which address biomarker development in Alzheimer's disease, and use their findings to suggest further research.Some of these studies are early results from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a large multi-centre trial of biomarker modalities in patients with Alzheimer's disease, mild cognitive impairment (MCI) and cognitively healthy older controls with an emphasis on standardized imaging techniques across centres. Nestor et al . (2008) measured ventricular volume changes over time and found that MCI subjects had a faster rate of ventricular enlargement than controls, and that Alzheimer's disease subjects had an even faster rate. Most importantly, among participants with MCI, the rate of ventricular enlargement was higher in those who progressed to Alzheimer's disease than in those who did not. The authors estimate that using ventricular enlargement as a surrogate marker of treatment outcome could improve the power of a treatment trial significantly versus standard cognitive outcomes. Desikan et al . (2009) developed methods of automated MRI analysis of regional brain volumes with the goal of identifying differences between patients with MCI and healthy controls. Entorhinal and supramarginal gyrus cortical thickness and hippocampal volumes afforded the best discrimination between these two groups. The automated analysis tools were impressively reliable and yielded replicable results in two different cohorts and with many different MRI scanners. Querbes et al . (2009) developed a rapid automated method for measuring cortical thickness and found …
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom